You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 5,164,486

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,164,486

Title:	Method of inhibiting large cell formation
Abstract:	The invention relates to an anti-HIV agent comprising as an effective component a plasma protein of which the polarity of the amino group of the amino acid residue constituting the plasma protein is chemically modified into a negative moiety by a carboxylic acid, for example, by maleic anhydride or succinic anhydride. Plasma proteins modified with dicarboxylic anhydride, which are the effective components of the anti-HIV agent of this invention, inhibit the formation of large cells in mixed culturing of HIV infected cells and non-infected cells as well as the direct infection of helper T cells with HIV. They are very safe compounds and are expected to be applicable to the treatment of HIV infected patients.
Inventor(s):	Tsunoo; Hajime (Odawara, JP), Takami; Masao (Odawara, JP), Mizumoto; Kenji (Odawara, JP)
Assignee:	Meiji Milk Products Co., Ltd. (Tokyo, JP)
Application Number:	07/576,439
Patent Claims:	1. A method of inhabiting large cell formation, comprising administering to a subject in need thereof plasma protein of which the polarity of at least one amino acid group of the amino acid residues comprising said plasma protein has been chemically modified into a negative moiety. 2. The method of claim 1 in which said amino group has been chemically modified by treatment with a dicarboxylic acid anhydride. 3. The method of claim 2, wherein the dicarboxylic acid anhydride is maleic anhydride or succinic anhydride. 4. The method of claim 1 or 2, wherein said plasma protein is derived from a human or bovine source. 5. The method of claim 4, wherein said plasma protein is a member selected from the group consisting of human serum albumin, human immunoglobulin, human transferrin, human fibrinogen, and bovine serum albumin.

Details for Patent 5,164,486

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	2009-11-17
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	2009-11-17
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	2009-11-17
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978	⤷ Try a Trial	2009-11-17
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995	⤷ Try a Trial	2009-11-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.